Loading news...
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Liminatus
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Earnings and Valuation This table compares Athira
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Valuation and Earnings This table compares Liminatus
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares Athira Pharma and
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Profitability This table compares Prime Medicine and
Brings more than 25 years of biopharma business development and corporate strategy expertise Brings more than 25 years of biopharma business development and corporate strategy expertise
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / January 13, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQB:SASKF)(FRA:X5U) is pleased to announce that it has entered into a binding term sheet (the "Term Sheet") with Queen's Road Capital Investment Ltd. ("QRC") for a private placement (the "Offering") of USD$20 million (~CAD$27.7 million1) principal amount of unsecured convertible debentures of the Company (the "Debentures").
Hong Kong, Hong Kong--(Newsfile Corp. - January 13, 2026) - Queen's Road Capital Investment Ltd. (TSX: QRC) (the "Company" or "Queen's Road Capital") is pleased to announce that it has entered into an agreement with ATHA Energy Corp. (TSXV: SASK) ("ATHA Energy") whereby the Company will invest US$20,000,000 in ATHA Energy by way of convertible debenture.
Athira Pharma, Inc. (NASDAQ: ATHA - Get Free Report) insider Martin Javier San sold 1,644 shares of the company's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total transaction of $11,310.72. Following the completion of the transaction, the insider owned 10,189 shares
Athira Pharma, Inc. (NASDAQ: ATHA - Get Free Report) CEO Mark James Litton sold 2,586 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $6.88, for a total value of $17,791.68. Following the completion of the sale, the chief executive officer owned 40,828 shares in
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 2, 2026 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") announces the grant of an aggregate of 10,150,000 incentive stock options ("Options") and 1,300,000 restricted share units ("RSUs") to certain eligible participants, including certain directors and officers of the Company, under the Company's equity incentive plan (the "Plan"). One-third of the Options shall vest on the date of issuance thereof, one-third of the Options shall vest on the six-month anniversary of the date of issuance thereof, and the remaining one-third of the Options shall vest on the twelve-month anniversary of the date of issuance thereof.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS Newswire / December 19, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce that, further to its news releases of November 17, November 24, December 9, and December 15, 2025, the Company has closed the third and final tranche of its private placement financing (the "Offering") and has received proceeds of CDN $502,002.98 through the issuance of 7,142,900 flow-through units (the "FT Units") at CDN $0.07 per FT Unit and 33,333 non-flow-through units (the "NFT Units") at CDN $0.06 per NFT Unit. A total of CDN $3,500,028.99 was raised in the Offering, of which CDN $2,727,526.03 was raised in the first tranche, CDN $270,499.98 in the second tranche and CDN $502,002.98 in the third tranche.
Athira Pharma Inc. (NASDAQ: ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
In a remarkable pivot, Athira Pharma has a deal to test a promising breast cancer drug and landed $90 million in upfront funding from investors.
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations
Vancouver, British Columbia – December 11, 2025 – TheNewswire - Generation Uranium Inc. (TSXV:GEN, OTCQB: GENRF) (the “Company” or “Generation”) is pleased to see Atha Energy's success in exploration in the Angikuni Basin located south of the Companies Yath Project. Atha has now reported multiple discoveries at the RIB target area on November 20 th and December 10, 2025. All exploration drill holes at the RIB zone intersected uranium mineralization, (Atha press release, Dec 10, 2025) with up to 5.55% U3O8. These discoveries are a clear demonstration of both the Angikuni Basin's uranium potential and also the hard work and effective exploration of the Atha Energy team.
Maiden diamond drilling returns 4.33 g/t Au over 14.4m; geophysics defines large intrusive WHITE ROCK, BC / ACCESS Newswire / November 26, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to provide an exploration update from its Excelsior Springs Project in Nevada. Mammoth Minerals Limited (ASX:M79) (formerly Firetail Resources Limited) has been aggressively exploring Excelsior, per its option agreement to earn an 80% interest in the project over five years, providing Athena a free-carry to Definitive Feasibility Study thereafter (see press releases dated June 2, 2025, and August 22, 2025).
HIGHLIGHTS Assays confirm the Company's maiden drillhole, RIBN-DD-001, at the RIB North Discovery as the best exploration hole drilled to date at the Angilak Uranium Project; RIBN-DD-001 assays returned total composite uranium mineralization1 of 34.7 m encompassing seven zones from 287.0 m to 439.9 m (Figure 4) - surpassing what was reported in the release of preliminary results (September 23rd, 2025, News Release ); The widest continuous intersection in the hole - from 426.3 to 439.9 - returned 13.6 m of composite uranium mineralization1 grading 0.53% U3O8, including 1.1 m grading 4.81% U3O8 with the highest-grade sample returning 8.16% U3O8 over 0.5 m; Mineralization was first intersected in the sandstone over three intervals (between 287.0 m and 351.1 m). The fourth zone was intersected directly above the unconformity (located at 356.7m), extending into graphitic basement rock below.
Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 31, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company"), is pleased to announce that, further to its press release dated October 21, 2025, the Company has filed its final short form prospectus (the "Prospectus") with the securities commissions in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and New Brunswick and been issued a receipt (the "Receipt") by the British Columbia Securities Commission, as principal regulator, in connection with the qualification of up to 18,838,752 units (the "Units") of the Company issuable upon the exercise or deemed exercise of 17,126,138 special warrants ("Special Warrants") of the Company issued in connection with its previously announced private placement.